» Articles » PMID: 16267155

Cystatin C and Mortality Risk in the Elderly: the Health, Aging, and Body Composition Study

Overview
Specialty Nephrology
Date 2005 Nov 4
PMID 16267155
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

Kidney dysfunction is known to decrease life expectancy in the elderly. Cystatin C is a novel biomarker of kidney function that may have prognostic utility in older adults. The association of cystatin C with mortality was evaluated in a biracial cohort of black and white ambulatory elderly and compared with that of serum creatinine concentrations. The Health, Aging and Body Composition study is a cohort of well-functioning elderly that was designed to evaluate longitudinal changes in weight, body composition, and function. A total of 3075 participants who were aged 70 to 79 yr and had no disability were recruited at sites in Memphis, TN, and Pittsburgh, PA, between April 1997 and June 1998 with a follow-up of 6 yr. At entry, the mean cystatin C was 1.05 mg/L and the mean creatinine was 1.06 mg/dl. After 6 yr of follow-up, 557 participants had died. The mortality rates in each ascending cystatin C quintile were 1.7, 2.7, 2.9, 3.1, and 5.4%/yr. After adjustment for demographic risk factors, comorbid health conditions, and inflammatory biomarkers (C-reactive protein, IL-6. and TNF-alpha), each quintile of cystatin C was significantly associated with increased mortality risk compared with the lowest: Hazard ratios (HR; 95% confidence intervals) quintile 1, -1.0 (referent); quintile 2, -1.74 (1.21 to 2.50); quintile 3, -1.51 (1.05 to 2.18); quintile 4, -1.49 (1.04 to 2.13); and quintile 5, -2.18 (1.53 to 3.10). These associations did not differ by gender or race. Results were consistent for cardiovascular and other-cause mortality, but not cancer mortality. Creatinine quintiles were not associated with mortality after multivariate adjustment (HR: 1.0 [referent], 1.00 [0.72 to 1.39], 0.95 [0.68 to 1.32], 1.11 [0.79 to 1.57], 1.16 [0.86 to 1.58]). Cystatin C is a strong, independent risk factor for mortality in the elderly. Future studies should investigate whether cystatin C has a role in clinical medicine.

Citing Articles

Associations of serum cystatin C concentrations with total mortality and mortality of 12 site-specific cancers.

Huang C, Lu J, Yang J, Wang Z, Hang D, Fu Z Front Mol Biosci. 2024; 11:1209349.

PMID: 38725873 PMC: 11079135. DOI: 10.3389/fmolb.2024.1209349.


Health-related quality of life and DNA methylation-based aging biomarkers among survivors of childhood cancer.

Plonski N, Pan Y, Chen C, Dong Q, Zhang X, Song N J Natl Cancer Inst. 2024; 116(7):1116-1125.

PMID: 38445706 PMC: 11223852. DOI: 10.1093/jnci/djae046.


Validation of biomarkers of aging.

Moqri M, Herzog C, Poganik J, Ying K, Justice J, Belsky D Nat Med. 2024; 30(2):360-372.

PMID: 38355974 PMC: 11090477. DOI: 10.1038/s41591-023-02784-9.


Should Cystatin C eGFR Become Routine Clinical Practice?.

Spencer S, Desborough R, Bhandari S Biomolecules. 2023; 13(7).

PMID: 37509111 PMC: 10377068. DOI: 10.3390/biom13071075.


Association of a Blood-Based Aging Biomarker Index With Death and Chronic Disease: Cardiovascular Health Study.

Zhang X, Sanders J, Boudreau R, Arnold A, Justice J, Espeland M J Gerontol A Biol Sci Med Sci. 2023; 79(2).

PMID: 37464278 PMC: 10799760. DOI: 10.1093/gerona/glad172.